JP2006521111A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006521111A5 JP2006521111A5 JP2006507160A JP2006507160A JP2006521111A5 JP 2006521111 A5 JP2006521111 A5 JP 2006521111A5 JP 2006507160 A JP2006507160 A JP 2006507160A JP 2006507160 A JP2006507160 A JP 2006507160A JP 2006521111 A5 JP2006521111 A5 JP 2006521111A5
- Authority
- JP
- Japan
- Prior art keywords
- ephb4
- shows
- ephrin
- seq
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 description 101
- 210000004027 cell Anatomy 0.000 description 39
- 239000002773 nucleotide Substances 0.000 description 32
- 125000003729 nucleotide group Chemical group 0.000 description 32
- 102000006396 Ephrin-B2 Human genes 0.000 description 30
- 108010044090 Ephrin-B2 Proteins 0.000 description 30
- 206010028980 Neoplasm Diseases 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 24
- 101001049392 Homo sapiens Ephrin-B2 Proteins 0.000 description 22
- 102000047954 human EFNB2 Human genes 0.000 description 22
- 108020004459 Small interfering RNA Proteins 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 20
- 125000003275 alpha amino acid group Chemical group 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 230000006907 apoptotic process Effects 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 230000000692 anti-sense effect Effects 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 12
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 12
- 239000000523 sample Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 206010028851 Necrosis Diseases 0.000 description 10
- 230000017074 necrotic cell death Effects 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000035605 chemotaxis Effects 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 206010016654 Fibrosis Diseases 0.000 description 6
- 108091030071 RNAI Proteins 0.000 description 6
- 230000004761 fibrosis Effects 0.000 description 6
- 230000009368 gene silencing by RNA Effects 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 5
- 230000033115 angiogenesis Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 5
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 5
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 4
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 4
- 206010027406 Mesothelioma Diseases 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 210000005239 tubule Anatomy 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 108020004518 RNA Probes Proteins 0.000 description 3
- 239000003391 RNA probe Substances 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 102000012803 ephrin Human genes 0.000 description 3
- 108060002566 ephrin Proteins 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108010055323 EphB4 Receptor Proteins 0.000 description 2
- 101150112014 Gapdh gene Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000004709 cell invasion Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000005267 prostate cell Anatomy 0.000 description 2
- 238000010379 pull-down assay Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 231100000747 viability assay Toxicity 0.000 description 2
- 238000003026 viability measurement method Methods 0.000 description 2
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 238000010599 BrdU assay Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000030797 EphB4 Receptor Human genes 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101001017828 Homo sapiens Leucine-rich repeat flightless-interacting protein 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 102100033303 Leucine-rich repeat flightless-interacting protein 1 Human genes 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006427 angiogenic response Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000002787 antisense oligonuctleotide Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229930189065 blasticidin Natural products 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45443203P | 2003-03-12 | 2003-03-12 | |
| US45430003P | 2003-03-12 | 2003-03-12 | |
| PCT/US2004/007755 WO2004080425A2 (en) | 2003-03-12 | 2004-03-12 | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011157200A Division JP2011256179A (ja) | 2003-03-12 | 2011-07-15 | 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006521111A JP2006521111A (ja) | 2006-09-21 |
| JP2006521111A5 true JP2006521111A5 (enExample) | 2007-05-24 |
Family
ID=32994555
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006507160A Pending JP2006521111A (ja) | 2003-03-12 | 2004-03-12 | 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用 |
| JP2006507095A Expired - Fee Related JP4762889B2 (ja) | 2003-03-12 | 2004-03-12 | 血管形成及び腫瘍成長を阻止するための核酸化合物 |
| JP2011157200A Pending JP2011256179A (ja) | 2003-03-12 | 2011-07-15 | 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006507095A Expired - Fee Related JP4762889B2 (ja) | 2003-03-12 | 2004-03-12 | 血管形成及び腫瘍成長を阻止するための核酸化合物 |
| JP2011157200A Pending JP2011256179A (ja) | 2003-03-12 | 2011-07-15 | 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用 |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US7585967B2 (enExample) |
| EP (2) | EP1605961A4 (enExample) |
| JP (3) | JP2006521111A (enExample) |
| AU (3) | AU2004220459B2 (enExample) |
| CA (2) | CA2518898A1 (enExample) |
| WO (2) | WO2004080425A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887674B1 (en) * | 1998-04-13 | 2005-05-03 | California Institute Of Technology | Artery- and vein-specific proteins and uses therefor |
| AU2002951409A0 (en) * | 2002-09-16 | 2002-09-26 | North Western Adelaide Health Services | Methods for regulating cancer |
| WO2004028551A1 (en) | 2002-09-24 | 2004-04-08 | The Burnham Institute | Novel agents that modulate eph receptor activity |
| US7381410B2 (en) | 2003-03-12 | 2008-06-03 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| AU2004220459B2 (en) * | 2003-03-12 | 2010-08-05 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| JP4960859B2 (ja) * | 2004-03-12 | 2012-06-27 | バスジーン セラピューティクス，インコーポレイテッド | 血管形成及び腫瘍成長を阻害するためのポリペプチド化合物 |
| DK1730196T3 (da) | 2004-03-12 | 2011-03-28 | Vasgene Therapeutics Inc | EphB4-bindende antistoffer til inhibering af antiogenese og tumorvækst |
| JP2007320850A (ja) * | 2004-08-24 | 2007-12-13 | Kyowa Hakko Kogyo Co Ltd | 抗エフリンｂ２抗体 |
| EP2301963A1 (en) * | 2004-09-23 | 2011-03-30 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| CA2581430A1 (en) * | 2004-09-23 | 2006-03-30 | Vasgene Therapeutics, Inc. | Compositions and methods for detecting and treating tumors |
| DE102004054016A1 (de) * | 2004-11-09 | 2006-05-11 | Robert Bosch Gmbh | Steuergerät zum Steuern und/oder regeln mindestens einer Fahrzeugfunktion |
| AU2005307737C1 (en) * | 2004-11-18 | 2013-08-29 | The Board Of Trustees Of The University Of Illinois | Multicistronic siRNA constructs to inhibit tumors |
| AU2006203884B2 (en) * | 2005-01-06 | 2012-02-16 | Genentech, Inc. | Cancer prognostic, diagnostic and treatment methods |
| US7582438B2 (en) | 2005-01-27 | 2009-09-01 | Burnham Institute For Medical Research | EphB receptor-binding peptides |
| FR2889200B1 (fr) | 2005-07-27 | 2008-01-04 | Inst Vaisseaux Et Du Sang Ass | Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique |
| EP1937291A2 (en) * | 2005-09-23 | 2008-07-02 | Vasgene Therapeutics, Inc. | Use of ephrinb2 directed agents for the treatment of prevention of viral infections |
| ZA200806187B (en) * | 2006-01-20 | 2009-10-28 | Genentech Inc | Anti-EphrinB2 antibodies and methods using same |
| HUE037173T2 (hu) | 2006-08-08 | 2018-08-28 | Univ Bonn Rheinische Friedrich Wilhelms | 5'-Foszfát-oligonukleotidok szerkezete és alkalmazása |
| US20110052667A1 (en) * | 2007-06-28 | 2011-03-03 | Sylgen Laboratories, Inc. | Compositions and methods for inhibiting angiogenesis and tumorigenesis |
| BRPI0815399A2 (pt) | 2007-08-13 | 2019-09-24 | Vasgene Therapeutics Inc | tratamento de câncer usando anticorpos humanizados que se ligam ephb4 |
| ES2542033T3 (es) * | 2007-11-29 | 2015-07-29 | Molecular Health Gmbh | Receptor de eritropoyetina protector de tejido (NEPOR) y métodos de uso |
| US8357501B2 (en) | 2007-11-29 | 2013-01-22 | Molecular Health Gmbh | Tissue protective erythropoietin receptor (NEPOR) and methods of use |
| US9738680B2 (en) | 2008-05-21 | 2017-08-22 | Rheinische Friedrich-Wilhelms-Universität Bonn | 5′ triphosphate oligonucleotide with blunt end and uses thereof |
| WO2012112434A1 (en) * | 2011-02-14 | 2012-08-23 | Allergan, Inc. | Inhibiting aberrant blood vessel formation using retargeted endopeptidases |
| EP2508530A1 (en) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Purification of triphosphorylated oligonucleotides using capture tags |
| EP2712870A1 (en) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Novel RIG-I ligands and methods for producing them |
| JP2015071566A (ja) * | 2013-10-03 | 2015-04-16 | 住友ベークライト株式会社 | Ｆｇｆ４遺伝子増幅腫瘍の医薬組成物 |
| US20190343880A1 (en) * | 2016-12-14 | 2019-11-14 | Shinshu University | Chimeric antigen receptor gene-modified lymphocyte having cytocidal effect |
| US20200224239A1 (en) * | 2019-01-10 | 2020-07-16 | Massachusetts Institute Of Technology | Functional analysis of cancer cells |
| EP4158349A4 (en) * | 2020-05-28 | 2024-08-07 | Cytobay Inc. | Cytopathological staining |
| EP4105328A1 (en) | 2021-06-15 | 2022-12-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Antisense-oligonucleotides for prevention of kidney dysfunction promoted by endothelial dysfunction by ephrin-b2 suppression |
| WO2023224096A1 (ja) * | 2022-05-18 | 2023-11-23 | 国立研究開発法人国立がん研究センター | 共通がん抗原カクテルを利用した、がんワクチン、ｔｃｒ／ｃａｒ－ｔ細胞治療薬、コンパニオン診断方法、および血中循環がん細胞検出によるがんの発症リスク診断方法 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JPH04218000A (ja) * | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
| EP0590030B1 (en) | 1991-06-21 | 2004-09-29 | The Walter and Eliza Hall Institute of Medical Research | A receptor-type tyrosine kinase [human eph/elk-like kinase - hek] and use thereof |
| US5635177A (en) * | 1992-01-22 | 1997-06-03 | Genentech, Inc. | Protein tyrosine kinase agonist antibodies |
| EP0624192A1 (en) | 1992-01-22 | 1994-11-17 | New England Deaconess Hospital | Novel protein tyrosine kinases |
| US6331302B1 (en) * | 1992-01-22 | 2001-12-18 | Genentech, Inc. | Protein tyrosine kinase agonist antibodies |
| ATE348110T1 (de) | 1992-10-28 | 2007-01-15 | Genentech Inc | Hvegf rezeptor als vegf antagonist |
| AU685765B2 (en) | 1992-11-13 | 1998-01-29 | Amgen, Inc. | (Eck) receptor ligands |
| US5824303A (en) | 1992-11-13 | 1998-10-20 | Amgen Inc. | Eck receptor ligands |
| US5512591A (en) * | 1993-02-18 | 1996-04-30 | President And Fellows Of Harvard College | Treatments for diseases characterized by neovascularization |
| ES2152753B1 (es) | 1993-03-29 | 2001-09-01 | Ct Investig Energeticas Ciemat | Animales transgenicos para la determinacion de agentes que estimulan o reprimen la hiperproliferacion epidermica y el crecimiento del pelo |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US6303769B1 (en) * | 1994-07-08 | 2001-10-16 | Immunex Corporation | Lerk-5 dna |
| US5864020A (en) * | 1994-07-20 | 1999-01-26 | Genentech, Inc. | HTK ligand |
| AU3144195A (en) | 1994-07-26 | 1996-02-22 | Rutgers, The State University Of New Jersey | Human brain specific kinase |
| US5795734A (en) * | 1994-09-19 | 1998-08-18 | President And Fellows Of Harvard College | EPH receptor ligands, and uses related thereto |
| DE69532857T2 (de) | 1994-10-27 | 2005-04-28 | Genentech Inc., San Francisco | Neurotrophischer AL-1 Faktor, einer Ligand verwandt mit dem EPH Tyrosine Kinase Receptor |
| US6057124A (en) | 1995-01-27 | 2000-05-02 | Amgen Inc. | Nucleic acids encoding ligands for HEK4 receptors |
| WO1996026958A2 (en) | 1995-02-27 | 1996-09-06 | President And Fellows Of Harvard College | Eph RECEPTOR LIGAND ELF-2 |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| DK0848755T4 (da) | 1995-09-08 | 2011-05-23 | Genentech Inc | VEGF relateret protein |
| US6346398B1 (en) * | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
| US5837534A (en) * | 1995-11-14 | 1998-11-17 | The Board Of Regents Of The University Of Texas System | Smooth muscle 22α promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells |
| AUPN727795A0 (en) | 1995-12-22 | 1996-01-18 | Walter And Eliza Hall Institute Of Medical Research, The | A novel receptor-type tyrosine kinase and use thereof |
| US6696557B1 (en) * | 1996-04-19 | 2004-02-24 | Genentech, Inc. | AL-2 neurotrophic factor nucleic acid |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| AU3251797A (en) * | 1996-07-05 | 1998-02-02 | Mount Sinai Hospital Corporation | Oligomerized receptors which affect pathways regulated by transmembrane ligands for elk-related receptor tyrosine kinases |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| WO1998045331A2 (en) | 1997-04-07 | 1998-10-15 | Genentech, Inc. | Anti-vegf antibodies |
| AU6887698A (en) | 1997-04-08 | 1998-10-30 | Sugen, Inc. | Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases |
| US6440954B1 (en) * | 1997-04-18 | 2002-08-27 | President And Fellows Of Harvard College | Inhibition of vascular smooth muscle cell proliferation |
| US6555321B1 (en) * | 1997-08-19 | 2003-04-29 | Vanderbilt University | Methods for determining cell responses through EphB receptors |
| EP1019080A2 (en) | 1997-10-02 | 2000-07-19 | Leukosite, Inc. | Modulation of lerk-2-mediated cell adhesion |
| US6423685B1 (en) * | 1998-03-05 | 2002-07-23 | Chiron Corporation | Method for increasing the serum half-life of a biologically active molecule |
| US6864227B1 (en) | 1998-04-13 | 2005-03-08 | California Institute Of Technology | Artery-and vein-specific proteins and uses therefor |
| US6887674B1 (en) * | 1998-04-13 | 2005-05-03 | California Institute Of Technology | Artery- and vein-specific proteins and uses therefor |
| CA2246664A1 (en) | 1998-10-02 | 2000-04-02 | Universite Paris 7 | Vascular specific regulatory elements contained in the desmin 5' flanking region |
| AUPP674898A0 (en) | 1998-10-27 | 1998-11-19 | Walter And Eliza Hall Institute Of Medical Research, The | A method of treatment |
| IL142921A0 (en) * | 1998-11-20 | 2002-04-21 | Genentech Inc | USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS |
| US6150162A (en) * | 1998-12-17 | 2000-11-21 | Isis Pharmaceuticals Inc. | Antisense modulation of CD44 expression |
| US6770633B1 (en) * | 1999-10-26 | 2004-08-03 | Immusol, Inc. | Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| EP1246637A2 (en) * | 2000-01-06 | 2002-10-09 | The Hospital for Sick Children | Methods of modulation of the immune system |
| WO2002081628A2 (en) * | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
| CA2400573A1 (en) * | 2000-03-28 | 2001-10-04 | Isis Pharmaceuticals Inc. | Alteration of cellular behavior by antisense modulation of mrna processing |
| EP2275557A1 (en) * | 2000-04-12 | 2011-01-19 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| MXPA02010351A (es) | 2000-04-21 | 2003-04-25 | Amgen Inc | Antagonistas de integrina/adhesion. |
| US6271030B1 (en) * | 2000-06-14 | 2001-08-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of C/EBP beta expression |
| US6277640B1 (en) * | 2000-07-31 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Antisense modulation of Her-3 expression |
| CA2417982A1 (en) | 2000-08-03 | 2002-02-14 | The University Of Utah Research Foundation | Manipulation of arterial-venous identity |
| US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| WO2002026827A1 (en) * | 2000-09-29 | 2002-04-04 | Novartis Ag | Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules |
| US7136808B2 (en) * | 2000-10-20 | 2006-11-14 | Microsoft Corporation | Detection and correction of errors in german grammatical case |
| ATE356640T1 (de) * | 2000-11-20 | 2007-04-15 | California Inst Of Techn | Für den glatten muskel von arterien und den glatten muskel von venen spezifische proteine und deren verwendung |
| KR100909681B1 (ko) * | 2000-12-01 | 2009-07-29 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자 |
| US6958140B2 (en) | 2001-01-26 | 2005-10-25 | Regeneron Pharmaceuticals, Inc. | Methods of imaging and targeting vasculature |
| CA2437194A1 (en) | 2001-01-31 | 2002-08-08 | Mount Sinai Hospital | Methods for regulating the kinase domain of ephb2 |
| CA2434881A1 (en) | 2001-02-02 | 2002-08-15 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Method for identifying functional nucleic acids |
| CA2442092A1 (en) * | 2001-03-26 | 2002-10-17 | Ribozyme Pharmaceuticals, Inc. | Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
| AU2002311792A1 (en) | 2001-03-30 | 2002-10-15 | President And Fellows Of Harvard College | B-ephrin regulation of g-protein coupled chemoattraction; compositions and methods of use |
| EP1390385A4 (en) * | 2001-05-29 | 2004-11-24 | Sirna Therapeutics Inc | MODULATION OF DISEASES AND DISEASES OF THE FEMALE REPRODUCTION SYSTEM BASED ON NUCLEIC ACID |
| KR100628425B1 (ko) | 2001-06-20 | 2006-09-28 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물 |
| AU2002314495A1 (en) | 2001-06-20 | 2003-01-02 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| CA2452578A1 (en) | 2001-07-03 | 2003-01-16 | The Hospital For Sick Children | Ephrin and eph receptor mediated immune modulation |
| JP3876656B2 (ja) * | 2001-07-13 | 2007-02-07 | 住友金属工業株式会社 | 管用ねじ継手 |
| AU2002353972A1 (en) * | 2001-11-02 | 2003-05-19 | Pfizer Products Inc. | Lung cancer therapeutics and diagnostics |
| US20060241027A1 (en) * | 2002-02-07 | 2006-10-26 | Hans-Peter Hauser | Hiv inhibiting proteins |
| AU2003243228B2 (en) | 2002-05-10 | 2009-03-26 | Medimmune, Llc | EphA2 monoclonal antibodies and methods of use thereof |
| EP1575509B1 (en) | 2002-05-10 | 2011-10-26 | Purdue Research Foundation | Epha2 agonistic monoclonal antibodies and methods of use thereof |
| US20040110150A1 (en) * | 2002-12-10 | 2004-06-10 | Isis Pharmaceuticals Inc. | Modulation of Ephrin-B2 expression |
| AU2003254641A1 (en) | 2002-08-28 | 2004-03-19 | Maxygen Aps | Interferon beta-like molecules for treatment of cancer |
| AU2002951409A0 (en) | 2002-09-16 | 2002-09-26 | North Western Adelaide Health Services | Methods for regulating cancer |
| AU2003260169B9 (en) * | 2002-09-16 | 2011-06-09 | The Queen Elizabeth Hospital Research Foundation Inc. | Methods for regulating cancer |
| EP2213738B1 (en) * | 2002-11-14 | 2012-10-10 | Dharmacon, Inc. | siRNA molecules targeting Bcl-2 |
| US7250289B2 (en) * | 2002-11-20 | 2007-07-31 | Affymetrix, Inc. | Methods of genetic analysis of mouse |
| AU2004220459B2 (en) | 2003-03-12 | 2010-08-05 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| AU2004223829A1 (en) * | 2003-03-24 | 2004-10-07 | Sequoia Pharmaceuticals, Inc. | Long acting biologically active conjugates |
| CA2521594A1 (en) | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Epha2 and non-neoplastic hyperproliferative cell disorders |
| CA2522082A1 (en) * | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution |
| US7604799B2 (en) | 2003-06-06 | 2009-10-20 | Medimmune, Llc | EphA4 Antibodies |
| EP2441474B1 (en) * | 2003-10-17 | 2015-08-05 | Joslin Diabetes Center, Inc. | Methods and compositions for modulating adipocyte function |
| JP4860477B2 (ja) | 2003-11-20 | 2012-01-25 | メディミューン，エルエルシー | ＥｐｈＡ２アゴニストモノクローナル抗体およびその使用法 |
| JP4960859B2 (ja) | 2004-03-12 | 2012-06-27 | バスジーン セラピューティクス，インコーポレイテッド | 血管形成及び腫瘍成長を阻害するためのポリペプチド化合物 |
| EP2301963A1 (en) | 2004-09-23 | 2011-03-30 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
-
2004
- 2004-03-12 AU AU2004220459A patent/AU2004220459B2/en not_active Ceased
- 2004-03-12 EP EP20040720444 patent/EP1605961A4/en not_active Withdrawn
- 2004-03-12 AU AU2004220525A patent/AU2004220525B2/en not_active Ceased
- 2004-03-12 CA CA002518898A patent/CA2518898A1/en not_active Abandoned
- 2004-03-12 US US10/800,077 patent/US7585967B2/en not_active Expired - Fee Related
- 2004-03-12 CA CA002518912A patent/CA2518912A1/en not_active Abandoned
- 2004-03-12 JP JP2006507160A patent/JP2006521111A/ja active Pending
- 2004-03-12 WO PCT/US2004/007755 patent/WO2004080425A2/en not_active Ceased
- 2004-03-12 US US10/800,350 patent/US7862816B2/en not_active Expired - Fee Related
- 2004-03-12 JP JP2006507095A patent/JP4762889B2/ja not_active Expired - Fee Related
- 2004-03-12 WO PCT/US2004/007491 patent/WO2004080418A2/en not_active Ceased
- 2004-03-12 EP EP04720327A patent/EP1606305A4/en not_active Withdrawn
-
2006
- 2006-10-06 US US11/544,855 patent/US8063183B2/en not_active Expired - Fee Related
-
2009
- 2009-09-01 US US12/552,185 patent/US20100093831A1/en not_active Abandoned
-
2010
- 2010-11-01 AU AU2010238577A patent/AU2010238577B2/en not_active Ceased
- 2010-11-23 US US12/952,593 patent/US20110129482A1/en not_active Abandoned
-
2011
- 2011-07-15 JP JP2011157200A patent/JP2011256179A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006521111A5 (enExample) | ||
| EP1429797B1 (en) | Diagnosis and treatment of malignant neoplasms | |
| JP4375932B2 (ja) | 悪性新生物の診断および処置 | |
| JP4762889B2 (ja) | 血管形成及び腫瘍成長を阻止するための核酸化合物 | |
| KR100304033B1 (ko) | 세포증식질환치료용약제학적조성물 | |
| Wang et al. | Antisense targeting of basic fibroblast growth factor and dibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth | |
| Maeshima et al. | Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo. | |
| JPH09507021A (ja) | サブトラクションｃＤＮＡライブラリーの作製方法および該作製されたライブラリーの使用 | |
| JP4698837B2 (ja) | 結合組織成長因子（ｃｔｇｆ）および使用方法 | |
| JP3844501B2 (ja) | 癌の制御 | |
| JP2002505841A (ja) | 低酸素調節性遺伝子 | |
| US7381410B2 (en) | Polypeptide compounds for inhibiting angiogenesis and tumor growth | |
| JP2023123748A (ja) | 転移性癌の診断及び治療の方法 | |
| JP2002525081A (ja) | 低酸素により調節される遺伝子転写に特徴的な配列 | |
| JP3398149B2 (ja) | Ｍｔｓ―１遺伝子による転移性の癌の診断 | |
| JPH09502094A (ja) | 老化細胞由来ｄｎａ合成阻害因子 | |
| JP2003501345A (ja) | 勃起不全の治療における血管内皮成長因子の使用 | |
| CN101712960A (zh) | Mac-2BP肿瘤抗原基因、蛋白、抗体及其用途 | |
| WO2000034466A1 (en) | Cervical cancer treatment | |
| WO2001019967A1 (en) | Human inflammatory breast carcinoma xenograft capable of lymphovascular invasion and methods for its use | |
| US6140119A (en) | Expression of estrogen receptors in type I and type II human breast epithelial cells | |
| WO2006123644A1 (ja) | 低酸素ストレス応答に関与するInt6タンパク質、およびその利用 | |
| HK1112510A (en) | Diagnosis and treatment of malignant neoplasms | |
| Li et al. | Adenovirus-mediated expression of pex, a noncatalytic fragment of matrix metalloproteinase-2, and it’s inhibition on angiogenesis and tumor growth | |
| WO2018133733A1 (zh) | 一种靶向rna解旋酶dhx33的小分子rna及其应用 |